Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Eduardo Dunayevich |
Documentos disponibles escritos por este autor (1)
Refinar búsqueda
Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation / Stephen R. Marder en The Journal of Clinical Psychiatry, Año 2010 - Vol. 71 - No. 4 (Abril)
[artículo]
Título : Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation Tipo de documento: texto impreso Autores: Stephen R. Marder, Autor ; Sebastian Sorsaburu, Autor ; Eduardo Dunayevich, Autor Fecha de publicación: 2022 Artículo en la página: pp. 433-441 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Benzodiazepinas, Trastorno bipolar, Agitación psicomotora, Esquizofrenia. Resumen: Agitation is a medical emergency with increased risk for poor outcome. Successful treatment often requires intramuscular (IM) psychotropics. Safety data from the first 21 months of olanzapine IM, approved in the United States for the treatment of agitation associated with schizophrenia and bipolar disorder, are presented. Link: ./index.php?lvl=notice_display&id=28171
in The Journal of Clinical Psychiatry > Año 2010 - Vol. 71 - No. 4 (Abril) . - pp. 433-441[artículo] Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation [texto impreso] / Stephen R. Marder, Autor ; Sebastian Sorsaburu, Autor ; Eduardo Dunayevich, Autor . - 2022 . - pp. 433-441.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The Journal of Clinical Psychiatry > Año 2010 - Vol. 71 - No. 4 (Abril) . - pp. 433-441
Palabras clave: Antipsicóticos, Benzodiazepinas, Trastorno bipolar, Agitación psicomotora, Esquizofrenia. Resumen: Agitation is a medical emergency with increased risk for poor outcome. Successful treatment often requires intramuscular (IM) psychotropics. Safety data from the first 21 months of olanzapine IM, approved in the United States for the treatment of agitation associated with schizophrenia and bipolar disorder, are presented. Link: ./index.php?lvl=notice_display&id=28171